Propofol With EDTAWhy It Is Still a Single-Dose Product

For Pfizer propofol sale NDC 0069-0209-10, EDTA does not change the single-dose designation. Its label-described growth inhibition does not confer antimicrobial preservation under United States Pharmacopeia (USP) standards; microbial growth can still occur. [1] [4]

Fictional AI-created staff scene. The native question map refers to the exact product’s labeling, reproduced below.

A product record can begin with a correct ingredient statement and end with an unsupported conclusion. "Contains EDTA, therefore preserved and suitable for multiple use" makes exactly that jump. The word "therefore" adds a permission that needs its own evidence.

To check the statement, read three parts of the exact product's labeling: what the ingredient does, how the formulation is classified and how the presentation is designated. Keeping those questions separate explains the apparent tension in the wording. It also gives the practice a precise way to correct its reference record without turning a catalog note into a handling protocol.

What EDTA does and does not change

Section 5.2 identifies 0.005% disodium edetate, or EDTA, and describes its limited growth-inhibition purpose in the event of accidental extrinsic contamination. [1]

EDTA does not change the single-dose designation

Exact Pfizer presentation. This comparison does not provide handling instructions. [1]

THREE QUESTIONS / ONE PRODUCT RECORD

Editorial analysis diagram. Each question is answered by its own part of the exact labeling.

PRACTICE + SCIENCE / VISUAL REFERENCE

Three questions. One product record.

Ingredient purposePreservation statusContainer designation

Conceptual artwork created with AI. A generic sealed vial containing opaque white liquid beside a reference folder. Product identity and instructions come from the cited sources, not this illustration.

Correct the inference in the reference record

Consider this hypothetical note: "Propofol contains EDTA, so classify it as preserved/multi-use."

Replace the incorrect note with: "Pfizer propofol, sale NDC 0069-0209-10: single-dose presentation. EDTA does not justify a multi-use classification." [1]

Keep the corrected note attached to its product

The DailyMed packaging record connects sale NDC 0069-0209-10 to immediate-vial NDC 0069-0209-01. [2] Keep both levels identified if the practice compares a carton record with an individual vial.

Original DailyMed label artwork: immediate vial at left and sale carton at right. The labeled package levels are distinct.

A reference note should travel with that exact product identity. If a proposed replacement has a different NDC or formulation, check its own label rather than copying the annotation across. The previous explanation may help frame the questions, but it does not establish the answers for another product.

Handling questions need the complete current prescribing information and the responsible clinical team. The source annotations here are intentionally limited to reading and correcting a product record. They should not become a stand-alone preparation, storage-after-opening or reuse instruction.

Clint product reference

Use the current Pfizer label beside the exact EDTA entry in Clint's propofol listings. Match the sale identifier before carrying the corrected description into the practice's reference record. Confirm the supplied ordering unit and current availability separately.

Sources and scope

1. Pfizer propofol label. Revised October 2025; sections 5.2 and 16.
2. Propofol packaging record. Updated September 18, 2026.
3. Clint propofol listings. Exact EDTA listing and navigation only; checked October 5, 2026.
4. FDA MOU 225-24-020. United States Pharmacopeia (USP) naming only; checked October 5, 2026.

Sources rechecked October 5, 2026. This is a product-identification reference; clinical decisions require the complete current labeling and the responsible clinical team.